Regeneron Pharmaceuticals, Inc. $REGN Stock: Tamar Securities LLC Lowers Holdings

Tamar Securities LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,753 shares of the biopharmaceutical company’s stock after selling 1,349 shares during the period. Regeneron Pharmaceuticals accounts for approximately 2.5% of Tamar Securities LLC’s investment portfolio, making the stock its 16th biggest position. Tamar Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $27,110,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $5,682,636,000. Legal & General Group Plc acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $473,872,000. Bank of New York Mellon Corp acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $472,950,000. Deutsche Bank AG acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $323,249,000. Finally, Man Group plc bought a new position in Regeneron Pharmaceuticals during the second quarter worth about $272,460,000. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

REGN has been the topic of a number of recent analyst reports. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $660.00 to $978.00 in a research report on Thursday, October 15th. Evercore raised their price target on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. Weiss Ratings upgraded shares of Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday. Finally, BMO Capital Markets lifted their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $898.97.

Insiders Place Their Bets

In related news, EVP Joseph Larosa sold 4,466 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the sale, the executive vice president owned 38,906 shares of the company’s stock, valued at $37,563,353.94. This represents a 10.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction on Friday, October 30th. The stock was sold at an average price of $900.00, for a total value of $360,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $542,700. This trade represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 28,228 shares of company stock valued at $25,985,950 in the last quarter. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded up $1.45 during midday trading on Friday, hitting $904.35. The company’s stock had a trading volume of 1,122,229 shares, compared to its average volume of 793,479. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $991.73. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66. The company has a 50-day moving average price of $804.38 and a two-hundred day moving average price of $742.81. The company has a market cap of $93.11 billion, a price-to-earnings ratio of 19.97, a PEG ratio of 1.51 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same quarter in the prior year, the business posted $11.83 EPS. The business’s revenue was up 36.3% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.